Asset profile
HY209gel
Small molecule
Evidence outlook · lead readout
NCT06024499 · Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06024499: The study randomized 210 participants to two HY209gel doses or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in EASI score at Week 8, but the comparison and treatment effects have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.